Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #1 Clear all
Not yet recruiting Phase 1Phase 2 Interventional

Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer

NCT07864584
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
NHT102, DryNeb
Drug · Device
Lead sponsor
Nob Hill Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-103
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

NCT04984993
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female), Tadalafil 5mg (Female)
Device · Drug
Lead sponsor
Futura Medical Developments Ltd.
Industry
Eligibility
22 Years to 70 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

NCT00307255
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 31, 2026, 11:08 PM EDT
Terminated Phase 4 Interventional Results available

Liposomal Bupivacaine in Vaginal Hysterectomy

NCT03907033
View directory record Official record
Conditions
Vaginal Hysterectomy
Interventions
Liposomal bupivacaine, Bupivacaine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

NCT01196052
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 31, 2026, 11:08 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

NCT01799889
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Interventions
Entospletinib MM, Entospletinib SDD
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 31, 2026, 11:08 PM EDT
Terminated Phase 1 Interventional

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

NCT04193904
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MRx0518, Hypofractionated Preoperative Radiation
Drug · Radiation
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin

NCT00970593
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
OAP-189, placebo comparator
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chula Vista, California • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

NCT00862823
View directory record Official record
Conditions
Healthy
Interventions
tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

NCT00383162
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Fresno, California • Newport Beach, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 31, 2026, 11:08 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

NCT07061288
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

NCT00125827
View directory record Official record
Conditions
Solid Tumors
Interventions
clofarabine (oral formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Dallas, Texas • Tyler, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 31, 2026, 11:08 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

NCT02446886
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

NCT05427162
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Prostacyclin Receptor Agonist
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

NCT00785291
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis, Nab-paclitaxel, Paclitaxel, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
703
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 472 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

NCT06742086
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Grayslake, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

NCT02954263
View directory record Official record
Conditions
Healthy Adults, Elderly Subjects
Interventions
TD-1439, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms

NCT02641912
View directory record Official record
Conditions
Xerostomia
Interventions
Biotene mouthwash, Mineral Water
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 31, 2026, 11:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2409021 Formulations in Healthy Participants

NCT02385084
View directory record Official record
Conditions
Healthy
Interventions
LY2409021
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 31, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

NCT04188730
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Lofexidine (granules for reconstitution), LUCEMYRA (lofexidine) tablets
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 31, 2026, 11:08 PM EDT